The future of Alzheimer's disease care is here, and it's time to revolutionize early detection and equitable access. This is a critical issue that deserves our attention and action.
On November 3, 2025, a diverse group of experts gathered in Boston, Massachusetts, to discuss the latest advancements and challenges in Alzheimer's disease management. The roundtable, hosted by The American Journal of Managed Care®, brought together neurologists, geriatricians, and researchers to explore how we can improve early diagnosis, address workforce gaps, and ensure equal access to innovative treatments.
But here's where it gets controversial...
While there's a growing recognition of the importance of addressing cognitive disorders, the panel highlighted significant system challenges and disparities. Michael Stanley, a cognitive neurologist, pointed out that national investment in Alzheimer's research and care still falls short, potentially due to lawmakers' perception of the disease as a lower priority.
And this is the part most people miss...
Even when health systems prioritize Alzheimer's care, frontline clinicians often lack the necessary resources. Medha Munshi, a geriatrician, emphasized the difficulty of treating patients without access to social workers, pharmacists, or community specialists. Sanford Auerbach, a behavioral neurologist, agreed, highlighting the time constraints faced by primary care doctors, which can hinder early identification of cognitive decline.
The benefits of early Alzheimer's diagnosis are clear: timely access to disease-modifying therapies and reduced crisis-driven healthcare utilization. However, the panel agreed that complex diagnosis processes and logistical barriers often lead to delayed diagnoses. Additionally, many primary care providers express discomfort and a lack of preparedness in diagnosing and managing Alzheimer's disease.
Technology to the rescue?
Artificial intelligence (AI) and digital tools offer promising solutions for early detection. Vijaya Kolachalama, an associate professor, described his lab's work on integrating AI into electronic health records to identify Alzheimer's risk. Brad Dickerson, a neurologist, suggested using validated cognitive surveys via email prompts to gather crucial information.
However, the panel warned against relying solely on at-home blood-based biomarker tests or AI-based tools. Christine Ritchie, a professor of medicine, raised concerns about the potential ramifications of at-home testing, especially for individuals with access to firearms.
Finding the balance between innovation and equity...
To address disparities, Pamela Woo Williams, a palliative care nurse practitioner, proposed a middle layer of assessment, where primary care providers can flag issues, and patients receive a mid-level assessment before a full neurology referral. This approach aims to bridge the gap between providers and ensure consistent screening efforts.
Breaking down stigma and fear...
Fear of cognitive decline discourages both patients and clinicians from seeking or making a diagnosis. Vanny McLean, a nurse practitioner, emphasized the need for community education to shift the narrative around Alzheimer's disease and highlight the opportunities for a good quality of life with proper management.
Expanding access to life-changing therapies...
The discussion shifted to treatment options, including symptom-relieving drugs and disease-modifying therapies. The FDA-approved drugs lecanemab and donanemab show promising results in slowing cognitive decline for those with mild dementia. However, ensuring equal access to these therapies remains a challenge due to limited infusion sites and long waitlists.
Equity-driven solutions are emerging. Christine Ritchie described a telehealth program connecting patients with dementia specialists, ensuring faster access for minoritized communities. To address the infusion seat shortage, creative alternatives like mobile infusion vans are being proposed.
A brighter future ahead?
The panel agreed that the combination of disease-modifying therapies, early prevention knowledge, AI capabilities, and attention to both pharmacological and non-pharmacological strategies offers the potential to reach a larger population. Michael Erkkinen, a cognitive neurologist, expressed optimism, believing that Alzheimer's disease will look very different in the future.
This roundtable discussion highlights the complex journey towards improving Alzheimer's disease care. While challenges remain, the experts' insights provide a roadmap for a more equitable and effective healthcare system for those affected by this debilitating disease.
What are your thoughts on the future of Alzheimer's disease care? Share your opinions and let's spark a conversation!
